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EDITORIAL



From Heresy to Standard of Care: A
Virologic Journey
SEE ARTICLE ON PAGE XXX
In this month’s issue, Bohorquez and colleagues(1)
review their experience with transplanting hepatitis
C virus (HCV)+ donor livers into HCV− recipients.
In a retrospective analysis, the authors report from
June 2018 to December 2019, following verification
of direct-acting antiviral (DAA) access, the absence of
critical drug–drug interactions, and informed consent,
allocated HCV Nucleic Acid Amplification Testing
(NAT+) organs were routinely offered to all patients
on the waiting list for liver transplantation irrespective of recipient HCV status. After excluding 47/339
HCV− recipients for HCV viremia, refusal to receive
HCV+ organs, or inability to receive DAA following transplantation, 61 HCV− recipients received an
HCV NAT+ liver and 231 HCV− recipients received
an HCV NAT− liver. Median time from transplant
to the start of DAA treatment was 66.9 days, and all
patients who completed DAA treatment achieved a
sustained virological response (SVR). At 1 year, both
patient and graft survival were similar between groups.
The authors conclude that this practice should now be
considered the standard of care.
What exactly is standard of care? Standard of care
is typically defined as the level and type of care that
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a reasonably competent and skilled health care professional, with a similar background and in the same
medical community, would provide to a patient under
specific circumstances. It can also be defined as “ . . .
not a guideline or list of options: instead, it is a duty
determined by a given set of circumstances that present in a particular patient, with a specific condition, at
a definite time and place.”(2) In other words, standard
of care defined as such is sensitive to person, time, and
place. Most medical therapies trace their beginnings
to attempts to help reduce the burden of disease using
the tools at hand while weighing the risks and benefits of the treatments. Early on, clinicians experienced
with hepatitis C in liver transplantation recognized the
deleterious effects of the virus, and the transplant community certainly did not endorse potential transmission of the virus during transplantation at that time.
So what has been our journey from a place where hepatitis C was a relative contraindication to transplant
to the place where this may now be considered the
standard of care to transmit the virus in the process of
transplantation?
Studies regarding liver transplantation for hepatitis C and the use of HCV+ donor organs date back
to the early 1990s. Despite findings of near 100%
persistent virus and recurrent hepatitis and fibrosis
following transplantation, the 5-year reported graft
and patient survivals were reported as similar when
compared with patients who were HCV−.(3,4) HCV+
donor organs when used in HCV+ recipients resulted
in similar graft and patient survivals compared with
HCV− donor organs.(5) At the time, prior to 1994,
donor organs met or exceeded the number of liver
transplantation registrants, allowing ample consideration and selection of donor organs for the pool of
patients awaiting liver transplantation.(6) During those
early years, treatment for HCV was limited to interferon and ribavirin, which were both poorly tolerated
and resulted in suboptimal SVR rates in transplant
recipients.(7) Therefore, when taking into account person, time, and place and given the limitations of available treatment, the standard of care was to transplant
HCV+ recipients with or without the use of HCV+
organs and with or without available antiviral therapy,
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but the use of HCV+ organs were restricted to HCV+
recipients.
In the years that followed, increasing numbers
of HCV+ transplanted patients coupled with longer
follow-up led to a realization that beyond 5 years, graft
and patient survivals were in fact inferior to those
patients who were HCV−. In a landmark article using
the United Network for Organ Sharing database,
Forman et al. found that liver transplantation in HCV+
recipients was associated with an increased rate of both
death and allograft failure compared with transplantation in HCV− recipients.(8) Numerous studies followed
that outlined the various factors likely contributing to
poorer outcomes. Given the documented increased risk
of reduced graft and patient survivals, consensus statements at that time focused on optimizing interferon
treatment to control infection in HCV+ recipients
while reinforcing the restricted use of HCV+ livers
in HCV+ recipients.(9,10) Despite these recommendations and the growing number of potential HCV+
recipients, the discard rate of HCV + organs remained
high.(11)
Long-term graft and patient survival data at the time
began to enforce the idea that if SVR could be achieved
with antiviral therapy, overall patient and graft survival rates from transplantation could be improved.(12)
With the introduction of DAAs, the challenge at that
time was the need for continued use of interferon in
combination with DAAs, which restricted the overall
potential benefit of treatment given the limited tolerance seen with interferon. However, as treatment
advanced with the introduction of second-generation
DAAs eliminating the need for interferon, increasing
numbers of HCV+ transplant recipients could now be
eligible for treatment. In 2015, data from the SOLAR
trials demonstrated that early posttransplant treatment
for HCV in liver transplantation recipients was both
well tolerated and resulted in 96% to 98% efficacy using
second-generation DAAs alone with or without ribavirin.(13) This was a major leap forward in our ability
to control the virus and improve transplant outcomes
for HCV recipients. Simultaneous with the availability of well-tolerated and highly efficacious treatment
for HCV in liver recipients was the rising number of
HCV+ donor organs, resulting from premature deaths
as a result of the advancing opioid crisis.(14) This was
paralleled by a decline of potential HCV+ recipients
in need of transplant because of improved clinical outcomes with treatment prior to liver failure. Other factors at play included the growing disparity between liver
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transplantation listings and available donor organs.(15)
The pressure to expand the organ pool demanded that
the transplant community investigate ways to now use
every possible available organ, including those that
were HCV+.
In 2017, a proof of concept for expanding the potential donor pool by using HCV+ organs in HCV− recipients came from the THINKER trial, showing that the
use of HCV+ kidneys could result in excellent graft
function and SVR in HCV− recipients receiving DAA
therapy.(16) These data sparked numerous case reports
and trials using HCV+ organs in HCV− liver, kidney,
heart, and lung recipients. All of the reports and trials
supported good early graft and patient outcomes, excellent medication tolerance, and high SVR.(17-20) In their
review of clinical practice for liver transplantation from
2008 to 2018, Cotter et al. used the Scientific Registry
of Transplant Recipients database to show a corresponding increase in the use of HCV livers in HCV− recipients from 7 in 2008 to 107 in 2018.(21) Their findings
confirmed the results from the numerous investigations
as noted previously, which showed graft and patient
outcomes using HCV+ organs as similar when compared with HCV− organs in HCV− recipients.
As Bohorquez et al. suggest in this month’s issue,
do we now consider the use of HCV+ organs as the
standard of care in HCV− recipients? The American
Society of Transplantation Consensus document
in 2017 concluded that there was a “need for well-
designed clinical trials with conclusive finding to justify
payer coverage of DAA medications.” Furthermore,
the authors concluded that the use of HCV+ organs
in HCV− recipients should be conducted under institutional review board–approved protocols and studies.
Since that time, there have been numerous studies
supporting both the safety and positive outcomes of
this policy as outlined previously. In 2019, there were
12,111 candidates waiting for liver transplantation,
8896 liver transplantations performed, and 1200 waitlist deaths.(15) The cumulative experience and data
confirm that HCV+ donor organs can be used safely
with adequate treatment and high SVR using current
DAA treatment. The combination of significant risk
of waitlist death in patients not receiving donor organs
should push us further to consider that now is the time
to consider using HCV+ organs as the standard of
care for all potential recipients with rigorous informed
consent and assurance of access to DAA therapy. The
journey from heresy to standard of care has been made
through the rigorous investigations by hundreds of
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authors who have defined the safety and the efficacy
of using HCV+ organs in HCV− recipients. I believe
the “standard of care” balancing the risks and potential
benefits of HCV+ organs in transplant recipients has
now been met.
Kimberly A. Brown, M.D., F.A.A.S.L.D., F.A.S.T.,
A.G.A.F.
Gastroenterology and Hepatology
Henry Ford Hospital
Detroit, MI
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